Concurrent validation program to be necessary for Stillen and Joins generics by 2012
Published: 2010-07-01 07:00:00
Updated: 2010-07-01 07:00:00
The Korea Food and Drug Administration says Korean firms producing a generic version of herbal medicines, such as Dong-A’s Stillen and SK Chemicals’ Joins, are obliged to perform concurrent validation program by 2012, adding that prospective validation should be necessary thereafter.
Under pro...
Fees
- Email service daily and homepage access.
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.
